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ABSTRACT  Vascular endothelial growth factor (VEGF) plays a key role in tumor 
angiogenesis. The notch ligand Delta-like ligand 4 (DLL4) is induced by VEGF and acts as a 
negative regulator of tumor angiogenesis by reducing the numbers of non-productive sprouting 
vessels. Several reports have shown the prognostic role of VEGF expression in non-small cell 
lung cancer. However, the correlation between VEGF and DLL4 expression and their clinical 
significance in non-small cell lung cancer remains unclear. The aim of this study was to analyze 
the correlation between the expression of VEGF/DLL4 and the clinicopathological background. 
Fifty-eight patients with lung adenocarcinomas measuring less than 3 cm in diameter who 
underwent surgical resection at Kawasaki Medical School Hospital from 2008 to 2010 were 
enrolled in this study. The expressions of VEGF, DLL4, CD31, and Ki-67 were analyzed using 
immunohistochemical staining. The tumor cells were VEGF-positive in 44 patients (75.9%) 
and DLL4-positive in 41 patients (70.7%). No statistically significant association was observed 
between the patients’ characteristics and VEGF/DLL4 expression. A high VEGF expression 
level tended to be associated with a high DLL4 expression level (P  = 0.050, r  = 0.258). The 
mean Ki-67 index was significantly lower in the patients with high VEGF expression (9.5 vs. 
18.2, P  = 0.011), but no significant difference was observed when patients were compared 
according to their DLL4 expression levels (11.8 vs. 11.0, P  = 0.804). The mean Ki-67 index was 
higher in the VEGFlow DLL4low patients than in the VEGFhigh DLL4high patients by a marginally 
significant difference (20.1 vs. 10.9 P  = 0.056). The 3-year recurrence-free survival rates of 
the VEGFhigh/DLL4high and the VEGFlow/DLL4low patients were 83.3% and 35.7%, respectively. 
The prognosis of the VEGFhigh/DLL4high patients was significantly better than that of the 
VEGFlow/DLL4low patients (P  = 0.032). To investigate the significance of the difference in tumor 
proliferation and prognosis between the VEGFhigh/DLL4high and the VEGFlow/DLL4low patients, 
we evaluated the morphologic effect of VEGF/DLL4 expression on the intratumoral capillaries 
by counting the number of capillaries and calculating the luminal area (μm2). No significant 
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INTRODUCTION
   Angiogenesis is required for the growth of 
several tumors. Vascular endothelial growth factor 
(VEGF) plays a major role in tumor angiogenesis1）. 
The notch signaling pathway is a regulator of 
differentiation and cell fate during the embryonic 
and postnatal phases2）. One of the notch ligands, 
Delta-like ligand 4 (DLL4), is induced by VEGF 
and acts downstream of VEGF as a brake on VEGF-
induced vessel growth, forming an autoregulatory 
negative feedback loop that inactivates VEGF3-5）.
   There were large numbers of reports showing a 
prognostic role for VEGF6,7）. Ping et al.8） reported a 
meta-analysis that suggested VEGF overexpression 
was an indicator of a poor prognosis for patients 
with adenocarcinoma or an early stage of non-
small cell lung cancer. Furthermore, some reports 
have shown that a high VEGF expression level was 
associated with a high intratumoral microvessel 
density in non-small cell lung cancer9-11）. On the 
other hand, in several tumor models, the blockade 
of DLL4 inhibited tumor growth by promoting 
nonproductive sprouting vessels12,13）.Recently, a 
high level of DLL4 expression has been shown to 
be an independent predictor of a poor prognosis 
in patients with several human malignancies14-16）. 
Conversely, Donnem et al.17） reported that a low 
DLL4 expression level in tumor cells was an 
independent negative prognostic factor in patients 
with lung adenocarcinoma. However, the correlation 
between VEGF and DLL4 expression and their 
clinical significance in non-small cell lung cancer 
remain unclear. In addition, the morphological effect 
of VEGF and DLL4 expression on intratumoral 
capillaries in vivo has never been reported. 
   In the present study, we evaluated the expressions 
of VEGF and DLL4 using immunochemistry in 
small pulmonary adenocarcinomas and compared the 
findings with the patients’ clinical factors as well 
as the Ki-67 index as a tumor proliferative marker. 
Furthermore, we examined the morphological effect 
of VEGF and DLL4 expression on intratumoral 
capillaries.
MATERIALS AND METHODS
Patients 
   Fifty-eight patients with lung adenocarcinomas 
measuring less than 3  cm in diameter who 
underwent surgical resection at Kawasaki Medical 
School Hospital from 2008 to 2010 were enrolled 
in this study. Because squamous cell carcinoma 
or large non-small cell lung cancers often have 
intratumoral necrosis,  we considered small 
adenocarcinomas were the most adequate to 
evaluate the impacts of VEGF/DLL4 in the similar 
background. None of the patients had received either 
radiotherapy or chemotherapy prior to undergoing 
surgery. The histologic tumor diagnoses were based 
on the criteria of the World Health Organization, 
and the TMN stage was determined according to the 
criteria published in 2009. Written informed consent 
was obtained from each patient for the study of 
excised tissue samples from the surgical specimens. 
This study was conducted with the approval of the 
Institutional Review Board of the Kawasaki Medical 
School (No. 589-4).
differences were seen between either the VEGF or DLL4 expression levels and the mean 
number of intratumoral capillaries or the luminal area (μm2). In conclusion, VEGFlow/DLL4low 
patients with small pulmonary adenocarcinoma had a significantly poorer prognosis, although 
no significant difference in a morphological evaluation of the capillaries was seen between 
VEGFhigh/DLL4high and VEGFlow/DLL4low patients.
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Immunohistochemical staining
   The VEGF, DLL4, CD31 and Ki-67 expression 
levels were evaluated using resected, paraffin-
embedded lung cancer tissues. After microtome 
sectioning (4-μm thick), tissue slides were processed 
using an automated immunostainer (NexES; Ventana 
Medical Systems, Tucson, AZ, USA) or manual 
methods. Streptavidin-biotin-peroxidase detection 
was performed, with diaminobenzidine used as the 
chromogen. The following primary antibodies were 
used according to the manufacturer's instructions: 
VEGF (rabbit polyclonal; sc-152; 1:300 dilution; 
Santa Cruze Biotechnology, Inc., Santa Cruz, 
CA, USA), DLL4 (rabitt polyclonal; ab7280; 
1:50 dilution; Abcam, Cambridge, MA, USA), 
Ki-67(mouse monoclonal; MIB-1 1:50 dilution; 
Dako, Carpenteria, CA, USA) and CD31 (mouse 
monoclonal; 1:50 dilution; Dako, Carpenteria, CA, 
USA). The immunohistochemical results were 
examined by two investigators who were blinded 
to the corresponding clinicopathological data. The 
expression of each protein marker was examined 
and evaluated according to previously reported 
protocols.
   VEGF expression was evaluated using the VEGF 
score18）,which was calculated by multiplying the 
staining proportion by the intensity of staining. The 
staining proportion was graded according to the 
percentage of stained cells as follows19）: 0 for no 
stained cells, 1 for 1% to 25%, 2 for 26% to 50%, 3 
for 51% to 75%, and 4 for greater than 75% of the 
tumor cells stained. The staining intensity was also 
Fig. 1.  Immunohistochemical staining for (A) vascular endothelial growth factor (VEGF), (B) delta-like ligand 4 (DLL4), (C) 
Ki-67, and (D) CD31 (x200).
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Table 1  Clinical characteristics and VEGF/DLL4 expression.
Characteristic No. ofPatients VEGF DLL4
(n=58) high low P high low P
44 14 41 17
　Age, years
　　Mean 69.2 68.1 72.9 0.083 69.8 67.9 0.471
　Sex
　　Female 29 22 7
0.999
20 9
0.773
　　Male 29 22 7 21 8
Pathological stage
I 55 42 13 39 16
Ⅱ 2 2 0 0.151 2 0 0.198
III 1 0 1 0 1
Lymph node metastasis
( － ) 55 43 12
0.142
40 15
0.203
( ＋ ) 3 1 2 1 2
Lymphatic invasion
( － ) 51 40 11
0.215
35 16
0.329
( ＋ ) 7 4 3 6 1
Vessel invasion
( － ) 46 34 12
0.397
30 16
0.069
( ＋ ) 12 10 2 11 1
Tumor diffrentiation
well 37 30 7 27 10
moderate 15 10 5 0.468 9 6 0.501
low/poor 6 4 2 5 1
divided into 4 grades. High VEGF expression was 
defined as a score of greater than 8, which was the 
overall median (Fig. 1A).
   To evaluate DLL4 staining in the tumor cells, 
the intensity of expression was scored using a 
semiquantitative scale in three x200 magnification 
fields. Negative cores were scored as 0, weak 
expression was scored as 1, moderate expression 
was scored as 2, and strong expression was scored 
as 3. High DLL4 expression was defined as a score 
of greater than 1.517） (Fig. 1B).
   To evaluate the proliferation potential of 
tumor cells, we used the labeling index of Ki-
67.  The labeling index of Ki-67 was measured by 
determining the percentage of cells with positively 
stained nuclei (Fig. 1C).
Evaluation of intratumoral capillaries
   To evaluate the intratumoral capillaries, we counted 
the whole numbers of CD31-positive capillaries and 
calculated the luminal area (μm2) of CD31-positive 
capillaries in three x200 magnification fields using 
Adobe Photoshop CS3, Extended (Adobe Systems 
Inc., San Jose, CA) (Fig. 1D). 
Statistical analysis
   The statistical analysis was performed using 
the Fisher exact test or the chi square (x2) test, 
as appropriate. An unpaired t-test was used to 
compare continuous data. A Kaplan-Meier survival 
analysis was performed to explore the association 
between VEGF/DLL4 expression and postoperative 
recurrence-free survival. All the analyses were 
performed using SPSS software, version 17.0 (SPSS 
Inc., Chicago, IL). All the statistical tests were two-
sided, and a probability value <0.05 was regarded as 
being statistically significant.
RESULTS
Relat ionship  be tween c l in icopathological 
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Table 2  Relationship between Ki-67 index and VEGF/DLL4 
expression.
Ki-67
index P
VEGF
high 9.5
0.011
low 18.2
DLL4
high 11.8
0.804
low 11.0
Table 3  Relationship between Ki-67 index and co-expression 
of VEGF/DLL4.
VEGF
high low
DLL4
high 10.9* 16.3
low 4.6 20.1*
*P =0.056
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Fig. 2.  Association between VEGF and DLL4 expression.
characteristics and VEGF/DLL4 expression
   The characteristics of the patients are summarized 
in Table 1. The patients ranged in age from 50 to 
89 years (mean, 69.2 years), and 29 were men. 
There were 44 VEGF-positive patients (75.9%) 
and 41  DLL4-positive patients (70 .7%). No 
statistically significant association was observed 
between the patients’ characteristics and the VEGF/
DLL4 expression levels. A high VEGF expression 
level tended to be associated with a high DLL4 
expression level (Fig. 2, P  = 0.050, r  = 0.258).
Relationship between Ki-67 index and VEGF/DLL4 
expression
   We evaluated the relationship between VEGF/
DLL4 expression and the labeling index of Ki-67 
(Table 2). The mean Ki-67 index was significantly 
lower in patients with high VEGF expression levels 
than in patients with low VEGF expression levels 
(9.5 vs. 18.2, P  = 0.011). However, no significant 
association was observed between the DLL4 
expression level and the Ki-67 index (11.8 vs. 11.0, 
P  = 0.804). The mean Ki-67 index was higher in 
the VEGFlow/DLL4low patients than in the VEGFhigh/
DLL4high patients by a marginally significant 
difference (20.1 vs. 10.9, P = 0.056) (Table 3).
Prognostic significance of co-expression of VEGF/
DLL4
   Postoperative recurrence-free survival was 
evaluated using a median follow-up period of 1077 
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days. The 3-year recurrence-free survival rates of 
VEGFhigh/DLL4high and VEGFlow/DLL4low patients 
were 83.3% and 35.7%, respectively (Fig. 3). 
The prognosis of VEGFhigh/DLL4high patients was 
significantly better than that of VEGFlow/DLL4low 
patients (P  = 0.032).
Morphological  evaluat ion of  intratumoral 
capillaries
   To investigate the cause of the significant 
difference in tumor proliferation and prognosis 
between the VEGFhigh/DLL4high and the VEGFlow/
DLL4low patients, we evaluated the morphological 
effect of VEGF/DLL4 expression in the intratumoral 
capillaries by counting the number of capillaries 
and calculating the luminal area (μm2). A total of 
2783 capillaries were analyzed in 58 patients. The 
mean number of capillaries per field was 48 (6-
118), and the mean luminal area of the capillaries 
was 1237.7 μm2 (279.8-2965.6 μm2). Regardless of 
the VEGF or DLL4 expression levels, there was 
no significant difference in the mean number 
of  in t ra tumoral  capi l la r ies  or  the  luminal 
area of the capillaries (μm2) (Table 4). Furthermore, 
Figure 3 
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Fig. 3.  Recurrence-free survival curves for VEGFhigh/DLL4high and VEGFlow/DLL4low patients.
Table 4  Mean number of capillaries and capillary area (μm2) 
according to VEGF/DLL4 expression.
number of
capillaries
capillary area
(μm2)
VEGF high 51.2 1147.1
low 44.5 1154.5
DLL4 high 50.7 1163.7
low 46.5 1108.6
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Table 5  Mean number of capillaries and capillary area(μm2) 
according to the co-expression of VEGF/DLL4.
number of capillaries VEGF
high low
DLL4
high 52.6 41.3
low 45.4 47.7
capillary area
of lumen (μm2) VEGF
high low
DLL4
high 1138.1 1288.3
low 1185.5 1020.6
no statistically significant differences in the mean 
number of intratumoral capillaries and the luminal 
area (μm2) were seen between the VEGFhigh/DLL4high 
and the VEGFlow/DLL4low patients (Table 5, Fig. 4).
DISCUSSION
   Our data showed that the Ki-67 index, which 
reflects tumor proliferation, was higher in VEGFlow/
DLL4low patients than in VEGFhigh/VEGFhigh patients 
by a marginally significant difference, and the 
VEGFlow/DLL4low patients had a significantly poorer 
prognosis than the VEGFhigh/DLL4high patients in 
terms of the 3-year recurrence-free survival rate in 
58 patients of adenocarcinoma less than 3cm. To 
our knowledge, this is the first report to show that 
VEGFlow/DLL4low patients with non-small cell lung 
cancer have a relatively poor prognosis.
   To investigate the cause of the significant 
difference in tumor proliferation and prognosis 
between VEGFhigh/DLL4high and VEGFlow/DLL4low 
patients, we evaluated the morphologic effect of 
VEGF/DLL4 expression in intratumoral capillaries 
by counting the number of  capil lar ies  and 
calculating the luminal area (μm2). VEGF/DLL4 
regulates angiogenetic sprouting and promotes the 
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Fig. 4.  Mean capillary area (μm2) according to the co-expression of VEGF/DLL4.
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formation of well-differentiated vascular networks3）.
We hypothesized that there might be a significant 
morphological difference between the VEGFhigh/
DLL4high and the VEGFlowDLL4low capillaries of 
tumors. However, our data showed that there was 
no statistically significant difference in either the 
intratumoral number of capillaries or the luminal 
area of the capillaries between the VEGFhigh/DLL4high 
and the VEGFlow/DLL4 low patients. We suspect 
that the in vivo network of intratumoral sprouting 
vessels might have been too fine to evaluate using 
light microscopy. In addition, the distribution of 
the capillary area was uneven because of cellular 
variations and tumor heterogeneity. An alternative 
method for evaluating tiny vascular network in vivo 
might need to be examined in a larger case series.
   In addition, our data had some limitations. 
First, even small lung adenocarcinomas have 
been reported to exhibit  varying malignant 
behaviors20,21）. This observation makes the present 
results more difficult to interpret. Second, we 
used immunohistochemical staining to analyze the 
VEGF and DLL4 expression levels. However, the 
evaluation of immunohistochemical staining might 
not be objective. Third, the present series contained 
only 58 patients. A larger number of cases is needed 
to analyze the prognostic role of VEGF and notch 
signals using clinical data from a matched cohort.
   In conclusion, VEGFlow/DLL4low patients with 
adenocarcinomas less than 3 cm in size had a 
significantly poorer prognosis than VEGFhigh/
DLL4high patients. However, no statistically 
significant difference in the number of intratumoral 
capillaries or the luminal area was seen between 
patients grouped according to their VEGF/DLL4 
expression levels. A larger number of cases is 
needed to analyze the prognostic role of VEGF/
DLL4 expression, and an alternative system is 
needed for performing in vivo evaluations of the 
tiny vascular network regulated by VEGF/DLL4.
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